Beyond phase 3 registration trials: Defining safety for triple therapy with protease inhibitors in cirrhosis

Gut

Volumn 63, Issue 7, 2014, Pages 1033-1034

  Ferenci, P ^a   Dusheiko, G ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; NOTE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REGISTRATION; RISK BENEFIT ANALYSIS; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL THERAPY; CIRRHOSIS; HEPATITIS C;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84902198731     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306480     Document Type: Note

References (14)

1. Fleming TR, DeMets DL. Surrogate End Points in Clinical Trials: Are We Being Misled? Ann Intern Med 1996;125:605-13. (Pubitemid 126450094)
2. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
6. Beinhardt S, Staettermayer AF, Rutter K, et al. Treatment of Chronic Hepatitis C GT 1 patients at an academic center in Europe involved in prospective controlled trials-Is there a selection bias? Hepatology 2012;55:30-8.
7. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access program (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59:434-41.
8. Rutter K, Ferlitsch A, Maieron A, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitic C patients with advanced liver diseasepredictive factors for sepsis. J Hepatol 2013;58:S30.
9. Backus LI, Belperio PS, Shahoumian TA, et al. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014;39:93-103.
10. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013;8:e55285.
11. Colombo M, Fernández I, Abdurakhmanov D, et al. Safety and on-treatment efficacy of telaprevir: The early access programme for patients with advanced hepatitis C. Gut 2014;63:1150-8.
12. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54: 396-405.
13. Reiberger T, Rutter K, Ferlitsch A, et al. Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients with HCV infection. Clin Gastroenterol Hepatol 2011;9:602-6.
14. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. Published Online First: 11 Oct 2013. doi:10.1053/j.gastro.2013.10.012.